English | 简体中文 | 繁體中文 | 한국어
 Trad. Chinese Press Releases
 Medicine BioTech
中國抗體SM17針對治療哮喘疾病的新藥研究申請獲國家藥監局批准
Aug 14, 2023 21:11 HKT
四環醫藥「創新藥+醫美」雙輪驅動戰略成效顯著
Aug 07, 2023 19:15 HKT
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
Aug 01, 2023 20:14 HKT
沛嘉醫療啟動TaurusTrio反流瓣膜 內地多中心註冊臨床研究首日入組成功完成
Aug 01, 2023 16:46 HKT
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成
Jul 26, 2023 18:59 HKT
HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies
Jul 24, 2023 20:19 HKT
沛嘉醫療公佈2023年上半年度未經審核營運數據
Jul 21, 2023 20:51 HKT
ADC國際化潛力受捧 科倫博泰或享龍頭估值溢價
Jul 20, 2023 20:12 HKT
萊盟健康LAMH董事長兼CEO張澤躍上榜《財富》「40位40歲以下的商界精英」榜單
Jul 19, 2023 18:20 HKT
Veteran Healthcare Communicator Lea Sims Appointed to Lead CGFNS Marketing and Communications
Jul 11, 2023 19:23 HKT
科倫博泰登陸港交所:搶跑ADC賽道 核心產品商業化潛力突出
Jul 11, 2023 15:19 HKT
科倫博泰即將上市:核心產品研發進度全球領先 市場廣闊長期投資價值凸顯
Jul 10, 2023 15:05 HKT
沛嘉醫療神經介入產品DCwire(TM)微導絲註冊申請獲藥監局批准
Jul 07, 2023 15:59 HKT
四環醫藥(0460.HK)旗下惠升生物研發的司美格魯肽注射液獲批開展臨床實驗
Jul 05, 2023 09:50 HKT
科倫博泰招股進行中 創新藥浪潮下何以大放異彩?
Jun 30, 2023 10:32 HKT
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Jun 29, 2023 18:45 HKT
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
Jun 29, 2023 17:00 HKT
四環醫藥:旗下軒竹生物創新藥品安奈拉唑鈉腸溶片獲國家藥監局批准上市
Jun 27, 2023 13:01 HKT
Prenetics與全球知名科學家盧煜明教授宣布成立2億美元合資企業「Insighta」推出突破性多種癌症早期篩查檢測
Jun 26, 2023 09:38 HKT
沛嘉醫療TaurusTrio經導管主動脈瓣系統獲批NMPA創新醫療器械綠色通道
Jun 14, 2023 10:50 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: